Literature DB >> 29203195

2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Gordon F Tomaselli, Kenneth W Mahaffey, Adam Cuker, Paul P Dobesh, John U Doherty, John W Eikelboom, Roberta Florido, William Hucker, Roxana Mehran, Steven R Messé, Charles V Pollack, Fatima Rodriguez, Ravindra Sarode, Deborah Siegal, Barbara S Wiggins.   

Abstract

Entities:  

Keywords:  ACC Expert Consensus Decision Pathway; atrial fibrillation; deep vein thrombosis; factor II; factor X; gastrointestinal bleeding; intracranial hemorrhage; vitamin K

Mesh：

Substances：

Year:  2017        PMID： 29203195     DOI： 10.1016/j.jacc.2017.09.1085

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  70 in total

1.  Transient or extended reversal of apixaban anticoagulation by andexanet alfa is equally effective in a porcine polytrauma model.

Authors:  Oliver Grottke; Till Braunschweig; Rolf Rossaint; Necib Akman; Janet M Leeds; Pamela B Conley; Markus Honickel
Journal:  Br J Anaesth       Date:  2019-06-13       Impact factor: 9.166

Review 2.  Perioperative management of oral anticoagulation.

Authors:  K McIlmoyle; H Tran
Journal:  BJA Educ       Date:  2018-07-30

3.  Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.

Authors:  Melanie N Smith; Lindsay Deloney; Cassandra Carter; Kyle A Weant; Evert A Eriksson
Journal:  J Thromb Thrombolysis       Date:  2019-08       Impact factor: 2.300

4.  Ten things ICU specialists need to know about direct oral anticoagulants (DOACs).

Authors:  Jakob Stensballe; Morten Hylander Møller
Journal:  Intensive Care Med       Date:  2018-04-25       Impact factor: 17.440

Review 5.  Fixed-dose 4-factor prothrombin complex concentrate: we don't know where we're going if we don't know how to get there.

Authors:  Scott T Hall; Kyle C Molina
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

6.  Drug plasma level measurement in management of severe bleeding during direct oral anticoagulant treatment: case report and perspective.

Authors:  Dimitriy Arioli; Davide Donelli; Lorenzo Morini; Maria Cristina Leone; Emanuele Alberto Negri
Journal:  Intern Emerg Med       Date:  2018-05-03       Impact factor: 3.397

7.  Andexanet Alfa (Andexxa®) for the Reversal of Direct Oral Anticoagulants.

Authors:  Jayed H Momin; PharmD Candidate; Gregory J Hughes
Journal:  P T       Date:  2019-09

8.  Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism.

Authors:  Meritxell Mellado; Javier Trujillo-Santos; Behnood Bikdeli; David Jiménez; Manuel Jesús Núñez; Martin Ellis; Pablo Javier Marchena; Jerónimo Ramón Vela; Albert Clara; Farès Moustafa; Manuel Monreal
Journal:  Intern Emerg Med       Date:  2019-05-03       Impact factor: 3.397

Review 9.  [Hemorrhage under direct oral anticoagulants : Occurrence and treatment in intensive care patients].

Authors:  H M Hoffmeister; H Darius; M Buerke
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-05-04       Impact factor: 0.840

Review 10.  Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.

Authors:  Michelangelo Sartori; Benilde Cosmi
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.